pioglitazone has been researched along with Alloxan Diabetes in 186 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to explore the role of pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, in cardiac fibrosis of diabetic mice." | 8.02 | Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway. ( Guo, JJ; Hu, CC; Sun, GX; Sun, RC; Yu, HC; Zhang, XD, 2021) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 7.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "It is evident from the present study that vildagliptin has an influence on the biomarkers linked to the progression of thrombosis and may delay thrombogenesis linked to DM." | 7.81 | Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. ( Akhtar, M; Khan, S; Najmi, AK; Panda, BP, 2015) |
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 7.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 7.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| "The present study investigates the effect of pioglitazone treatment on blood pressure, vascular reactivity and antioxidant enzymes in L-NAME induced hypertension in normal and STZ-diabetic rats." | 7.73 | Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. ( Balaraman, R; Majithiya, JB; Parmar, AN; Trivedi, CJ, 2005) |
| "To explore the effects of pioglitazone on MKP-1 and TSP-1 expression in the early stages of diabetic retinopathy induced by streptozotocin (STZ) and the relevant mechanism in it." | 7.73 | [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]. ( Kong, JX; Shen, JG; Wang, JY, 2006) |
| "Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported." | 6.41 | [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. ( Ikeda, H; Sugiyama, Y, 2001) |
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 5.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Type 2 diabetes was induced in male Sprague-Dawley rats by combination of high fat diet and low dose streptozotocin (35mg/kg)." | 5.48 | Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. ( Abdel-Rahman, N; Eissa, LA; Eraky, SM, 2018) |
| "Inflammation is a known risk factor in diabetes." | 5.43 | Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation. ( Ge, J; Jin, X; Liu, L; Shen, C; Yao, T; Zhou, Z, 2016) |
| "Pioglitazone (10mg/kg; po) was administered daily for 2 weeks prior to I/R." | 5.42 | Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. ( Ain-Shoka, AA; Attia, AS; El-Sahar, AE; Safar, MM; Zaki, HF, 2015) |
| "A rat model of type 2 diabetes (T2D) was established with streptozotocin (STZ)." | 5.39 | Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. ( Hu, SH; Jiang, T; Yang, SS; Yang, Y, 2013) |
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 5.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Pioglitazone treatment for 8 weeks affected GSH-Px activity in diabetic liver (261." | 5.33 | Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals. ( Gumieniczek, A, 2005) |
| "The aim of this study was to explore the role of pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, in cardiac fibrosis of diabetic mice." | 4.02 | Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway. ( Guo, JJ; Hu, CC; Sun, GX; Sun, RC; Yu, HC; Zhang, XD, 2021) |
| "Pioglitazone belongs to the class of drugs thiazolidinediones (TZDs) and is an oral hypoglycemic drug, used in the treatment of type 2 diabetes, which improves insulin sensitivity in target tissues." | 3.96 | MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice. ( Araújo Dos Santos, B; Araújo, HN; da Paixão, AO; de Mendonça, M; de Sousa, É; Imamura de Lima, T; Murata, GM; Passos Simões Fróes Guimarães, DS; Rodrigues, AC; Roveratti Spagnol, A; Silveira, LR, 2020) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 3.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "It is evident from the present study that vildagliptin has an influence on the biomarkers linked to the progression of thrombosis and may delay thrombogenesis linked to DM." | 3.81 | Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. ( Akhtar, M; Khan, S; Najmi, AK; Panda, BP, 2015) |
| "Our study indicates that combination therapy with canagliflozin and pioglitazone improves insulin sensitivity partly by preventing glucotoxicity and, at least partly, by attenuating pioglitazone-induced body weight gain in two different obese diabetic animal models." | 3.81 | Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. ( Arakawa, K; Horai, Y; Kuriyama, C; Nakayama, K; Senbonmatsu, T; Shiotani, M; Taniuchi, N; Ueta, K; Watanabe, Y, 2015) |
| "To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism." | 3.80 | Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. ( Bai, SJ; Gao, X; Ye, XM; Zhang, J; Zhang, M, 2014) |
| "Administration of rutin (50 and 100 mg/kg) and pioglitazone (10 mg/kg) orally for 3 weeks treatment significantly improved body weight, reduced plasma glucose and glycosylated hemoglobin, pro-inflammatory cytokines (IL-6 and TNF-alpha), restored the depleted liver antioxidant status and serum lipid profile in high fat diet + streptozotocin induced type 2 diabetic rats." | 3.80 | Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. ( Ansari, AA; Naik, SR; Niture, NT, 2014) |
| "Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD." | 3.79 | Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. ( Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL, 2013) |
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 3.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| " In addition to measuring BW, circulating glucose level, and BP, the following procedures were also carried out: insulin challenge (insulin sensitivity), losartan challenge (renin-angiotensin system activity), Nw-nitro-L arginine-methyl ester hydrochloride (LNAME) challenge (nitric oxide [NO] system activity), and evaluation of serum angiotensin converting enzyme (ACE) activity." | 3.78 | Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats. ( Bagchi, D; Echard, B; Fu, J; Kaylor, M; Perricone, NV; Preuss, HG; Zhuang, C, 2012) |
| "Hydrogen saturated saline showed great efficiency in improving the insulin sensitivity and lowering blood glucose and lipids." | 3.78 | Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress. ( Huang, Q; Kang, ZM; Wang, QJ; Xu, MJ; Zha, XJ; Zou, DJ, 2012) |
| " Six weeks following streptozotocin or saline injection, gastric ulcers were induced by serosal application of acetic acid." | 3.77 | Role of activation of 5'-adenosine monophosphate-activated protein kinase in gastric ulcer healing in diabetic rats. ( Baraka, AM; Deif, MM, 2011) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 3.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| " All rats were examined for body weight, serum and hepatic biochemical indices, content of malondialdehyde (MDA), activities of superoxide dismutase (SOD) and pathological changes in liver and pancreas, as well as protein tyrosine phosphatase 1B (PTP1B) expression in liver." | 3.76 | Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats. ( Cheng, WM; Hu, XY; Li, J; Lu, YX; Sun, YX; Wang, LY; Zhang, Q, 2010) |
| "By using a hindlimb ischemia murine model, in this study we have found that pioglitazone restores the blood flow recovery and capillary density in ischemic muscle of diabetic mice and that this process is associated with increased expression of Vascular Endothelial Growth Factor (VEGF)." | 3.75 | Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. ( Arena, V; Biscetti, F; De Angelis, G; Flex, A; Ghirlanda, G; Iuliano, L; Pecorini, G; Rizzo, P; Stigliano, E; Straface, G, 2009) |
| "To observe the changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone and to elucidate the possible mechanism involved and the effects of thiazolidinediones compound pioglitazone on the early stages of diabetic retinopathy." | 3.74 | [The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone]. ( Shen, F; Wang, JY; Zhang, HY; Zhang, XM, 2007) |
| "To explore the effects of pioglitazone on MKP-1 and TSP-1 expression in the early stages of diabetic retinopathy induced by streptozotocin (STZ) and the relevant mechanism in it." | 3.73 | [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]. ( Kong, JX; Shen, JG; Wang, JY, 2006) |
| "The present study investigates the effect of pioglitazone treatment on blood pressure, vascular reactivity and antioxidant enzymes in L-NAME induced hypertension in normal and STZ-diabetic rats." | 3.73 | Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. ( Balaraman, R; Majithiya, JB; Parmar, AN; Trivedi, CJ, 2005) |
| "In order to evaluate the relationship between tumour necrosis factor-alpha (TNF-alpha) level in muscle and metabolic abnormalities in obesity and diabetes mellitus, pioglitazone, a novel insulin-sensitizing agent, was administered to Wistar fatty rats and time-dependent changes in muscle TNF-alpha content and plasma indicators of diabetes and obesity were measured." | 3.70 | Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. ( Ikeda, H; Murase, K; Odaka, H; Suzuki, M; Tayuki, N, 1998) |
| " We investigated the effect of pioglitazone, a thiazolidinedione compound, on the development of multiple low-dose streptozotocin (MLDS)-induced autoimmune diabetes in mice." | 3.70 | Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. ( Ando, H; Kobayashi, K; Nagai, Y; Nohara, E; Takamura, T; Yamashita, H, 1999) |
| "Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported." | 2.41 | [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. ( Ikeda, H; Sugiyama, Y, 2001) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| "As pioglitazone is an insulin sens MSDC-itizer used for diabetes, its MPC inhibitory effect in diabetic individuals was investigated." | 1.91 | Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming. ( Chen, CC; Chen, LC; Chen, YJ; Chien, WC; Chung, CH; Huang, CN; Huang, KY; Liao, NS; Lin, HA; Lin, HC; Lin, YY; Ojcius, DM; Shih, CT; Tsai, KJ; Wang, JY, 2023) |
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 1.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Atorvastatin monotherapy was effective at reducing cholesterol (from 4." | 1.62 | Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. ( Awortwe, C; Joubert, E; Louw, J; Muller, CJF; Patel, O; Rosenkranz, B, 2021) |
| " To estimate the pharmacokinetic parameters, the diabetic animals were assigned to 2 groups: one group received PIO (10 mg/kg), while the other received PIO + caffeine (20 mg/kg)." | 1.62 | Caffeine modulates pharmacokinetic and pharmacodynamic profiles of pioglitazone in diabetic rats: Impact on therapeutics. ( Alkahtani, SA; Alshabi, AM; Habeeb, MS; Shaikh, IA, 2021) |
| "However, insulin resistance was ameliorated by pioglitazone with or without fish oil treatment and the discontinuation of fish oil." | 1.56 | Impact of discontinuation of fish oil after pioglitazone-fish oil combination therapy in diabetic KK mice. ( Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M, 2020) |
| "Rats were tested for thermal hyperalgesia and mechanical allodynia." | 1.56 | Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. ( El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA, 2020) |
| "It is the compensatory hyperinsulinemia rather than insulin resistance per se that causes blood pressure elevation." | 1.56 | Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats. ( Chen, Y; Li, G; Pan, L; Shen, X; Tian, Y; Wang, H, 2020) |
| "Pioglitazone was given orally [10mg/kg/day] for 28 days and adiponectin intraperitoneally [2." | 1.56 | Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats. ( Abdul Sattar, M; Afzal, S; Eseyin, OA; Johns, EJ, 2020) |
| "Pioglitazone (PGZ) is an antidiabetic agent belongs to thiazolidinediones." | 1.51 | Physicochemical and pharmacodynamic evaluation of pioglitazone binary systems with hydrophilic carriers. ( Abou El Ela, AESF; Al-Amin, MA; Al-Rasheed, NM; Ibrahim, MA, 2019) |
| "Type 2 diabetes was induced in male Sprague-Dawley rats by combination of high fat diet and low dose streptozotocin (35mg/kg)." | 1.48 | Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. ( Abdel-Rahman, N; Eissa, LA; Eraky, SM, 2018) |
| "TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity." | 1.48 | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus. ( Fan, Y; He, Z; Hu, A; Li, J; Xiong, W; Yin, Q; Zhang, J; Zhou, G, 2018) |
| "Pioglitazone (PIO) is a thiazolidindione antidiabetic agent which improves insulin sensitivity and reduces blood glucose in experimental animals and treated patients." | 1.48 | Effects of pioglitazone on ventricular myocyte shortening and Ca(2+) transport in the Goto-Kakizaki type 2 diabetic rat. ( Howarth, FC; Oz, M; Qureshi, M; Salem, KA; Sydorenko, V, 2018) |
| "Significant differences were seen in pharmacokinetic parameters of pioglitazone like AUC, t1/2, Ke, Cl/F, Vd/F when given in combination with cinnamon in normal and diabetic rabbits." | 1.46 | Effect of Cinnamomum cassia on the Pharmacokinetics and Pharmacodynamics of Pioglitazone. ( Koganti, B; Koganti, VSRGP; Mamindla, S; Ravouru, N, 2017) |
| "Pioglitazone is an anti-diabetic drug with potential to cause adverse effects following prolonged use." | 1.46 | Quercetin and pioglitazone synergistically reverse endothelial dysfunction in isolated aorta from fructose-streptozotocin (F-STZ)-induced diabetic rats. ( Achike, FI; Kunasegaran, T; Murugan, DD; Mustafa, MR, 2017) |
| "Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-γ as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats." | 1.46 | Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017) |
| "Pioglitazone (PIO) has been found to exert an anti-inflammatory effect in patients with diabetes mellitus, but it is still unclear whether PIO exhibits a similar effect in DN." | 1.46 | Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus. ( Wang, L; Wang, Y; Wei, W; Xia, Z; Yang, M; Yu, B; Yuan, X; Zhang, F, 2017) |
| "Pioglitazone is an effective drug for the treatment of type 2 diabetes." | 1.46 | Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone. ( Doble, M; Nankar, RP, 2017) |
| "Pioglitazone was generally more effective than vildagliptin in the studied parameters except for the lipid profile where the effect of both drugs was comparable and for the liver enzymes and renal parameters where vildagliptin was more effective." | 1.43 | Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. ( El Sarha, A; Refaat, R; Sakr, A; Salama, M, 2016) |
| "Inflammation is a known risk factor in diabetes." | 1.43 | Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation. ( Ge, J; Jin, X; Liu, L; Shen, C; Yao, T; Zhou, Z, 2016) |
| " Therefore, we tested the hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker Diabetic Fatty (ZDF(fa/fa) [ZDF]) rats." | 1.43 | Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. ( Adkins, BG; Anderson, KL; Donahue, RR; Griggs, RB; Taylor, BK; Thibault, O, 2016) |
| "Vildagliptin treatment significantly increased BMD and trabecular bone volume." | 1.43 | Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. ( Eom, YS; Gwon, AR; Kim, BJ; Kim, JY; Kim, KW; Kim, YS; Kwak, KM; Lee, K; Lee, S; Park, IB; Yu, SH, 2016) |
| "Pioglitazone (10mg/kg; po) was administered daily for 2 weeks prior to I/R." | 1.42 | Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. ( Ain-Shoka, AA; Attia, AS; El-Sahar, AE; Safar, MM; Zaki, HF, 2015) |
| "Hyperglycemia was induced by streptozotocin treatment." | 1.42 | Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. ( Gliem, M; Hartung, HP; Jander, S; Klotz, L; van Rooijen, N, 2015) |
| "Their anti-type 2 diabetes activity was evaluated in HepG2 cell and db/db mice." | 1.42 | Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity. ( Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G, 2015) |
| "With pioglitazone-treatment, diabetic animals remained euglycemic and treatment was able to reverse the clearance changes, although incompletely." | 1.42 | Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. ( Chadha, GS; Morris, ME, 2015) |
| "Diabetic hyperglycemia has been suggested to play a role in osteoarthritis." | 1.42 | PPARγ is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages. ( Chan, DC; Chao, SC; Chen, CM; Chen, YJ; Lan, KC; Liu, SH; Tsai, KS; Wang, CC; Yang, RS, 2015) |
| "Chronic pain is a common complication of diabetes." | 1.42 | Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. ( Byrne, FM; Chapman, V; Cheetham, S; Vickers, S, 2015) |
| " Dosages-dependent analysis revealed that protective effect of PIO ameliorated the physiopathological changes and reached a peak at dosage of 20 mg/kg/d." | 1.40 | Hydrochloride pioglitazone protects diabetic rats against podocyte injury through preserving glomerular podocalyxin expression. ( Chen, Y; Hu, W; Xing, Y; Ye, S, 2014) |
| "The pioglitazone was administrated intragastrically, and normal saline was given to the contro group in the same way." | 1.40 | [Effect of pioglitazone on the expression of TLR4 in renal tissue of diabetic rats]. ( Wen, G; Wu, Y; Yang, W; Yu, Y, 2014) |
| "The objective of the current study was to assess the possible pharmacokinetic interactions of spirulina with glitazones in an insulin resistance rat model." | 1.39 | Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model. ( Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A, 2013) |
| "Pioglitazone is a stimulator of nuclear receptor peroxisome proliferator-activated receptor gamma while alogliptin is a selective dipeptidyl peptidase IV inhibitor." | 1.39 | Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. ( Bell, GI; Chong, AS; Grossman, EJ; Misawa, R; Park, SY; Tao, J; Wang, XJ; Witkowski, P; Yin, H; Zhong, R, 2013) |
| "Pioglitazone ameliorates memory deficits in STZ-induced diabetic mice by reducing brain Aβ level via activation of PPARγ, which is independent of its effects on blood glucose and insulin levels." | 1.39 | Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. ( Hong, H; Hu, M; Hu, W; Jiang, LY; Li, YQ; Liu, LP; Long, Y; Wang, C; Wang, JQ; Yan, TH; Zhang, Q, 2013) |
| "A rat model of type 2 diabetes (T2D) was established with streptozotocin (STZ)." | 1.39 | Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. ( Hu, SH; Jiang, T; Yang, SS; Yang, Y, 2013) |
| " In conclusion, PIO and OLM combination can primarily be stated as safe in terms of present toxicity and pharmacokinetics findings." | 1.38 | Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. ( Nandi, U; Pal, TK; Sengupta, P, 2012) |
| "Pioglitazone was able to also protect against hyperglycemia and cytokine-induced elevations in cytosolic Ca(2+) levels, insulin-secretory defects, and cell death." | 1.38 | PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. ( Ahn, G; Evans-Molina, C; Fueger, PT; Gann, L; Kono, T; Moss, DR; Nishiki, Y; Ogihara, T; Zarain-Herzberg, A, 2012) |
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 1.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Pioglitazone was used as a hypoglycemic drug for comparison." | 1.38 | Antioxidant and anti-inflammatory effects of a hypoglycemic fraction from Cucurbita ficifolia Bouché in streptozotocin-induced diabetes mice. ( Alarcon-Aguilar, FJ; Almanza-Perez, JC; Angeles-Mejia, S; Banderas-Dorantes, TR; Blancas-Flores, G; Diaz-Flores, M; Fortis-Barrera, A; Gomez, J; Jasso, I; Roman-Ramos, R; Zamilpa-Alvarez, A, 2012) |
| "Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats." | 1.38 | Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. ( Hu, W; Liu, D; Yu, Q; Zhang, J, 2012) |
| "In pioglitazone-treated animals, AA and TAS increased above control values while GSH and PCG were normalized." | 1.38 | Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. ( Gumieniczek, A; Owczarek, B; Pawlikowska, B, 2012) |
| "Treatment with pioglitazone orMNCs, demonstrated a significant improvement in the STZ-induced renal functional and structural changes in comparison with diabetic control group." | 1.38 | Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats. ( Abd El-All, HS; Ewais, MM; Masoad, RE; Tawfik, MK, 2012) |
| "Treatment with pioglitazone or telmisartan demonstrated a significant improvement in the reperfusion-induced renal injury in comparison with diabetic I/R group, without difference between the two treated groups." | 1.38 | Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. ( Tawfik, MK, 2012) |
| " The aim of this study was to elucidate potential pharmacokinetic interaction between RA and pioglitazone, and to provide guidance for clinical medicine safety." | 1.38 | Herb-drug pharmacokinetic interaction between radix astragali and pioglitazone in rats. ( Gao, JW; Huang, M; Huang, P; Lu, YS; Shi, Z; Yao, MC; Yuan, YM, 2012) |
| "pioglitazone treatment increased fat mass and the surface area of adipocytes more than rosiglitazone at dosages with equivalent effects on plasma glucose." | 1.36 | Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice. ( Gang, GT; Hwang, JH; Kim, YH; Lee, CH; Noh, JR; Yang, KJ; Yang, SJ; Yeom, YI, 2010) |
| "Pioglitazone and insulin treatments, but not metformin, reduced hyperglycemia, polydipsia, and polyphagia." | 1.35 | Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes. ( Andreotti, S; Borges-Silva, Cd; Campana, AB; de Campos, TB; Fonseca-Alaniz, MH; Lima, FB; Machado, UF; Okamoto, M; Takada, J, 2008) |
| "Pioglitazone treatment markedly corrected the above abnormalities." | 1.34 | Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Noguchi, E, 2007) |
| "Obesity is a common and serious metabolic disorder in the developed world that is occasionally accompanied by type II diabetes, atherosclerosis, hypertension, and hyperlipidemia." | 1.33 | Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size. ( Ezaki, O; Kamei, Y; Takahashi, M, 2005) |
| "Pioglitazone treatment for 8 weeks affected GSH-Px activity in diabetic liver (261." | 1.33 | Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals. ( Gumieniczek, A, 2005) |
| "Pioglitazone is a new oral antidiabetic agent with potent antioxidant and anti-inflammatory properties." | 1.33 | Interleukin-6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment. ( Bojarska-Junak, A; Gumieniczek, A; Hopkała, H; Roliński, J, 2006) |
| "Pioglitazone treatment reduced blood pressure without having any significant effect on blood glucose level and body weight of STZ-diabetic rats." | 1.33 | Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. ( Balaraman, R; Majithiya, JB; Paramar, AN, 2005) |
| "Pioglitazone treatment showed no effect on plasma glucose levels in the control group." | 1.32 | Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats. ( Anjaneyulu, M; Ramarao, P, 2003) |
| "Treatment with pioglitazone thus protects against beta-cell damage and would be useful for restoration of insulin secretory capacity in obese diabetes individuals." | 1.32 | Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. ( Ishida, H; Itagaki, E; Katahira, H; Katsuta, H; Maruyama, M; Nagamatsu, S; Nakamichi, Y; Ozawa, S; Takizawa, M; Tanaka, T; Yamaguchi, S; Yoshimoto, K, 2004) |
| "Pioglitazone treatment, which can attenuate the decrease of glomerular MMP-2 and the increase of C-IV degradation, has curative effects on diabetic nephropathy." | 1.32 | Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. ( Cai, WM; Dong, FQ; Li, H; Li, Q; Ruan, Y; Tao, J; Zhang, Z; Zheng, FP, 2004) |
| "Pioglitazone treatment slightly normalised glucose and insulin levels, with a slight reduction in mPai-1 gene expression." | 1.32 | Night-time restricted feeding normalises clock genes and Pai-1 gene expression in the db/db mouse liver. ( Akiyama, M; Kudo, T; Kuriyama, K; Moriya, T; Shibata, S; Sudo, M, 2004) |
| "Pioglitazone treatment during 4 weeks decreased the catalase activity in relation to the control diabetic animals." | 1.32 | Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. ( Gumieniczek, A, 2003) |
| "Troglitazone was able to prevent not only diabetic glomerular hyperfiltration and albuminuria, but an increase in mRNA expression of extracellular matrix proteins and transforming growth factor-beta1 in glomeruli of diabetic rats, without changing blood glucose levels." | 1.31 | Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. ( Haneda, M; Isshiki, K; Kikkawa, R; Koya, D; Maeda, S; Sugimoto, T, 2000) |
| "Pioglitazone treatment of diabetic animals significantly enhanced the effects of insulin to reverse elevated blood glucose." | 1.29 | Insulin sensitization in diabetic rat liver by an antihyperglycemic agent. ( Colca, JR; Hofmann, C; Lorenz, K; Palazuk, BJ; Williams, D, 1995) |
| "Treatment with pioglitazone alone is sufficient for correction of glucose transport in hyperinsulinemic insulin-resistant animals, but hypoinsulinemic animals require insulin therapy along with pioglitazone treatment for similar corrections." | 1.28 | Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. ( Colca, JR; Hofmann, C; Lorenz, K, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (10.22) | 18.2507 |
| 2000's | 39 (20.97) | 29.6817 |
| 2010's | 99 (53.23) | 24.3611 |
| 2020's | 29 (15.59) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 2 |
| Blanchard, SG | 1 |
| Brackeen, MF | 1 |
| Brown, KK | 1 |
| Cobb, JE | 1 |
| Collins, JL | 1 |
| Harrington, WW | 1 |
| Hashim, MA | 1 |
| Hull-Ryde, EA | 1 |
| Kaldor, I | 1 |
| Kliewer, SA | 1 |
| Lake, DH | 1 |
| Leesnitzer, LM | 2 |
| Lehmann, JM | 1 |
| Lenhard, JM | 1 |
| Orband-Miller, LA | 1 |
| Miller, JF | 1 |
| Mook, RA | 1 |
| Noble, SA | 1 |
| Oliver, W | 1 |
| Parks, DJ | 1 |
| Plunket, KD | 2 |
| Szewczyk, JR | 1 |
| Willson, TM | 2 |
| Liu, KG | 1 |
| Lambert, MH | 1 |
| Ayscue, AH | 1 |
| Oliver, WR | 1 |
| Xu, HE | 1 |
| Sternbach, DD | 1 |
| Yamamoto, K | 1 |
| Itoh, T | 1 |
| Abe, D | 1 |
| Shimizu, M | 1 |
| Kanda, T | 1 |
| Koyama, T | 1 |
| Nishikawa, M | 1 |
| Tamai, T | 1 |
| Ooizumi, H | 1 |
| Yamada, S | 1 |
| Mohammed Iqbal, AK | 1 |
| Khan, AY | 1 |
| Kalashetti, MB | 1 |
| Belavagi, NS | 1 |
| Gong, YD | 1 |
| Khazi, IA | 1 |
| Nazreen, S | 3 |
| Alam, MS | 3 |
| Hamid, H | 3 |
| Yar, MS | 2 |
| Dhulap, A | 3 |
| Alam, P | 3 |
| Pasha, MA | 3 |
| Bano, S | 3 |
| Alam, MM | 3 |
| Haider, S | 3 |
| Kharbanda, C | 3 |
| Ali, Y | 3 |
| Pillai, KK | 2 |
| Shafi, S | 1 |
| Fan, L | 1 |
| Wang, J | 2 |
| Ma, X | 1 |
| Xiao, W | 1 |
| Li, Z | 1 |
| Zhong, G | 1 |
| Tang, L | 1 |
| Wu, H | 1 |
| Patel, OP | 1 |
| Mishra, A | 1 |
| Maurya, R | 1 |
| Saini, D | 1 |
| Pandey, J | 1 |
| Taneja, I | 1 |
| Raju, KS | 1 |
| Kanojiya, S | 1 |
| Shukla, SK | 1 |
| Srivastava, MN | 1 |
| Wahajuddin, M | 1 |
| Tamrakar, AK | 1 |
| Srivastava, AK | 1 |
| Yadav, PP | 1 |
| Hamouda, HA | 1 |
| Mansour, SM | 1 |
| Elyamany, MF | 1 |
| Katahira, S | 1 |
| Sugimura, Y | 1 |
| Grupp, S | 1 |
| Doepp, R | 1 |
| Selig, JI | 1 |
| Barth, M | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Lule, KO | 1 |
| Akarsu, E | 1 |
| Sayiner, ZA | 1 |
| Lule, NO | 1 |
| Balci, SO | 1 |
| Demirel, C | 1 |
| Bozdag, Z | 1 |
| Korkmaz, M | 1 |
| Yilmaz, I | 1 |
| Sharma, DK | 1 |
| Pattnaik, G | 1 |
| Behera, A | 1 |
| Piątkowska-Chmiel, I | 1 |
| Herbet, M | 1 |
| Gawrońska-Grzywacz, M | 1 |
| Dudka, J | 1 |
| Hao, CL | 1 |
| Lin, HL | 2 |
| Cheng, PW | 2 |
| Tu, YC | 2 |
| Yeh, BC | 2 |
| Wu, BN | 2 |
| Shen, KP | 2 |
| Guo, Y | 1 |
| Zuo, W | 1 |
| Yin, L | 1 |
| Gu, T | 1 |
| Wang, S | 1 |
| Fang, Z | 1 |
| Wang, B | 1 |
| Dong, H | 1 |
| Hou, W | 1 |
| Zuo, Z | 1 |
| Deng, J | 1 |
| Zakaraya, ZZ | 1 |
| AlTamimi, L | 1 |
| Hailat, M | 2 |
| Ahmad, MN | 1 |
| Qinna, NA | 1 |
| Ghanim, BY | 1 |
| Saadh, MJ | 2 |
| Al-Dmour, N | 1 |
| Dayyih, WA | 1 |
| Tamimi, LN | 1 |
| Zakaraya, Z | 1 |
| Abu Dayyih, W | 1 |
| Daoud, E | 1 |
| Abed, A | 1 |
| Majeed, B | 1 |
| Abumansour, H | 1 |
| Aburumman, A | 1 |
| Majeed, JM | 1 |
| Hamad, M | 1 |
| Chen, LC | 1 |
| Chen, YJ | 2 |
| Lin, HA | 1 |
| Chien, WC | 1 |
| Tsai, KJ | 1 |
| Chung, CH | 1 |
| Wang, JY | 3 |
| Chen, CC | 1 |
| Liao, NS | 1 |
| Shih, CT | 1 |
| Lin, YY | 1 |
| Huang, CN | 1 |
| Ojcius, DM | 1 |
| Huang, KY | 1 |
| Lin, HC | 1 |
| Kralova, E | 2 |
| Hadova, K | 1 |
| Cinakova, A | 2 |
| Krenek, P | 2 |
| Klimas, J | 2 |
| Gupta, S | 2 |
| Baweja, GS | 1 |
| Singh, S | 1 |
| Irani, M | 1 |
| Singh, R | 1 |
| Asati, V | 1 |
| Kamel, R | 1 |
| El-Batanony, R | 1 |
| Salama, A | 1 |
| Wang, Z | 2 |
| Liu, Q | 1 |
| Dai, W | 1 |
| Hua, B | 1 |
| Li, H | 4 |
| Li, W | 3 |
| Ruddarraju, RR | 1 |
| Kiran, G | 1 |
| Murugulla, AC | 1 |
| Maroju, R | 1 |
| Prasad, DK | 1 |
| Kumar, BH | 1 |
| Bakshi, V | 1 |
| Reddy, NS | 1 |
| Hasan, MM | 1 |
| El-Shal, AS | 1 |
| Mackawy, AMH | 1 |
| Ibrahim, EM | 1 |
| Abdelghany, EMMA | 1 |
| Saeed, AA | 1 |
| El-Gendy, J | 1 |
| Iizuka, Y | 1 |
| Chiba, K | 1 |
| Kim, H | 1 |
| Hirako, S | 1 |
| Wada, M | 1 |
| Matsumoto, A | 1 |
| de Mendonça, M | 1 |
| de Sousa, É | 1 |
| da Paixão, AO | 1 |
| Araújo Dos Santos, B | 1 |
| Roveratti Spagnol, A | 1 |
| Murata, GM | 1 |
| Araújo, HN | 1 |
| Imamura de Lima, T | 1 |
| Passos Simões Fróes Guimarães, DS | 1 |
| Silveira, LR | 1 |
| Rodrigues, AC | 1 |
| Tahara, A | 1 |
| Takasu, T | 1 |
| Cam, ME | 1 |
| Yildiz, S | 1 |
| Alenezi, H | 1 |
| Cesur, S | 1 |
| Ozcan, GS | 1 |
| Erdemir, G | 1 |
| Edirisinghe, U | 1 |
| Akakin, D | 1 |
| Kuruca, DS | 1 |
| Kabasakal, L | 1 |
| Gunduz, O | 1 |
| Edirisinghe, M | 1 |
| Elkholy, SE | 1 |
| Elaidy, SM | 1 |
| El-Sherbeeny, NA | 1 |
| Toraih, EA | 1 |
| El-Gawly, HW | 1 |
| Tedesco, S | 1 |
| Ciciliot, S | 1 |
| Menegazzo, L | 1 |
| D'Anna, M | 1 |
| Scattolini, V | 1 |
| Cappellari, R | 1 |
| Cignarella, A | 1 |
| Avogaro, A | 1 |
| Albiero, M | 1 |
| Fadini, GP | 1 |
| Wang, H | 1 |
| Tian, Y | 1 |
| Chen, Y | 4 |
| Shen, X | 3 |
| Pan, L | 2 |
| Li, G | 2 |
| Maheshwari, RA | 1 |
| Parmar, GR | 1 |
| Hinsu, D | 1 |
| Seth, AK | 1 |
| Balaraman, R | 3 |
| Bakkar, NZ | 1 |
| Mougharbil, N | 1 |
| Mroueh, A | 1 |
| Kaplan, A | 1 |
| Eid, AH | 1 |
| Fares, S | 1 |
| Zouein, FA | 1 |
| El-Yazbi, AF | 1 |
| Afzal, S | 2 |
| Abdul Sattar, M | 1 |
| Johns, EJ | 2 |
| Eseyin, OA | 2 |
| Alshabi, AM | 1 |
| Alkahtani, SA | 1 |
| Shaikh, IA | 1 |
| Habeeb, MS | 1 |
| Zhang, XD | 1 |
| Sun, GX | 1 |
| Guo, JJ | 1 |
| Hu, CC | 1 |
| Sun, RC | 1 |
| Yu, HC | 1 |
| Patel, O | 1 |
| Muller, CJF | 1 |
| Joubert, E | 1 |
| Rosenkranz, B | 1 |
| Louw, J | 1 |
| Awortwe, C | 1 |
| Hu, Y | 1 |
| Tao, R | 1 |
| Chen, L | 2 |
| Xiong, Y | 1 |
| Xue, H | 1 |
| Hu, L | 1 |
| Yan, C | 1 |
| Xie, X | 1 |
| Lin, Z | 1 |
| Panayi, AC | 1 |
| Mi, B | 1 |
| Liu, G | 1 |
| Shakour, N | 1 |
| Sahebkar, A | 1 |
| Karimi, G | 1 |
| Paseban, M | 1 |
| Tasbandi, A | 1 |
| Mosaffa, F | 1 |
| Tayarani-Najaran, Z | 1 |
| Ghodsi, R | 1 |
| Hadizadeh, F | 1 |
| Hidalgo-Figueroa, S | 1 |
| Navarrete-Vázquez, G | 1 |
| Estrada-Soto, S | 1 |
| Giles-Rivas, D | 1 |
| Alarcón-Aguilar, FJ | 2 |
| León-Rivera, I | 1 |
| Giacoman-Martínez, A | 1 |
| Miranda Pérez, E | 1 |
| Almanza-Pérez, JC | 2 |
| Gao, F | 1 |
| Zang, L | 1 |
| Wu, DY | 1 |
| Li, YJ | 1 |
| Zhang, Q | 4 |
| Wang, HB | 1 |
| Tian, GL | 1 |
| Mu, YM | 1 |
| Li, X | 1 |
| Wang, E | 1 |
| Yin, B | 1 |
| Fang, D | 1 |
| Chen, P | 2 |
| Wang, G | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Chen, W | 2 |
| Liu, C | 1 |
| Liu, R | 1 |
| Fu, H | 1 |
| Li, J | 4 |
| Wang, X | 1 |
| Cheng, L | 1 |
| Korantzopoulos, P | 1 |
| Tse, G | 1 |
| Liu, T | 1 |
| Wang, Y | 3 |
| Yu, B | 1 |
| Wang, L | 1 |
| Yang, M | 1 |
| Xia, Z | 1 |
| Wei, W | 1 |
| Zhang, F | 1 |
| Yuan, X | 1 |
| Eraky, SM | 1 |
| Abdel-Rahman, N | 1 |
| Eissa, LA | 1 |
| Adil, M | 1 |
| Mansoori, MN | 1 |
| Singh, D | 1 |
| Kandhare, AD | 1 |
| Sharma, M | 1 |
| Nankar, RP | 1 |
| Doble, M | 1 |
| Salem, KA | 1 |
| Sydorenko, V | 1 |
| Qureshi, M | 1 |
| Oz, M | 1 |
| Howarth, FC | 1 |
| Gao, H | 1 |
| Di, B | 1 |
| Abdelhamid, AM | 1 |
| Abdelaziz, RR | 1 |
| Salem, HAA | 1 |
| Shokrzadeh, M | 1 |
| Mirshafa, A | 1 |
| Yekta Moghaddam, N | 1 |
| Birjandian, B | 1 |
| Shaki, F | 1 |
| Sattar, MA | 1 |
| Akhtar, S | 1 |
| Binti Abdullah, NA | 1 |
| Abdulla, MH | 1 |
| Kim, TH | 1 |
| Lee, JH | 1 |
| Chae, YN | 1 |
| Jung, IH | 1 |
| Kim, MK | 1 |
| Mudassir, HA | 1 |
| Qureshi, SA | 1 |
| Azmi, MB | 1 |
| Ahsan, M | 1 |
| Matsuda, H | 1 |
| Mullapudi, ST | 1 |
| Yang, YHC | 1 |
| Masaki, H | 1 |
| Hesselson, D | 1 |
| Stainier, DYR | 1 |
| Fan, Y | 1 |
| Xiong, W | 1 |
| Hu, A | 1 |
| He, Z | 1 |
| Zhang, J | 3 |
| Zhou, G | 1 |
| Yin, Q | 1 |
| Ibrahim, MA | 1 |
| Abou El Ela, AESF | 1 |
| Al-Rasheed, NM | 1 |
| Al-Amin, MA | 1 |
| Hu, SH | 1 |
| Jiang, T | 1 |
| Yang, SS | 1 |
| Yang, Y | 1 |
| Liu, LP | 2 |
| Yan, TH | 1 |
| Jiang, LY | 2 |
| Hu, W | 4 |
| Hu, M | 3 |
| Wang, C | 1 |
| Long, Y | 2 |
| Wang, JQ | 1 |
| Li, YQ | 1 |
| Hong, H | 2 |
| Arikawe, AP | 1 |
| Oyerinde, A | 1 |
| Olatunji-Bello, II | 1 |
| Obika, LF | 1 |
| Yang, SC | 1 |
| Tseng, HL | 1 |
| Shieh, KR | 1 |
| Yin, H | 1 |
| Park, SY | 1 |
| Wang, XJ | 1 |
| Misawa, R | 1 |
| Grossman, EJ | 1 |
| Tao, J | 2 |
| Zhong, R | 1 |
| Witkowski, P | 1 |
| Bell, GI | 1 |
| Chong, AS | 1 |
| Zhao, ZQ | 1 |
| Luo, R | 1 |
| Li, LY | 1 |
| Tian, FS | 1 |
| Zheng, XL | 1 |
| Xiong, HL | 1 |
| Sun, LT | 1 |
| Gupta, A | 1 |
| Nair, A | 1 |
| Kumria, R | 1 |
| Al-Dhubiab, BE | 1 |
| Chattopadhyaya, I | 1 |
| Konda, VR | 1 |
| Desai, A | 1 |
| Darland, G | 1 |
| Grayson, N | 1 |
| Bland, JS | 1 |
| Novelli, M | 1 |
| Canistro, D | 1 |
| Martano, M | 1 |
| Funel, N | 1 |
| Sapone, A | 1 |
| Melega, S | 1 |
| Masini, M | 1 |
| De Tata, V | 1 |
| Pippa, A | 1 |
| Vecoli, C | 1 |
| Campani, D | 1 |
| De Siena, R | 1 |
| Soleti, A | 1 |
| Paolini, M | 1 |
| Masiello, P | 1 |
| Jin, HY | 1 |
| Lee, KA | 1 |
| Wu, JZ | 1 |
| Baek, HS | 1 |
| Park, TS | 1 |
| Yuan, M | 1 |
| Qiu, M | 1 |
| Cui, J | 1 |
| Zhang, X | 1 |
| Zhang, P | 1 |
| Zhang, M | 2 |
| Gao, X | 1 |
| Bai, SJ | 1 |
| Ye, XM | 1 |
| Takada, S | 1 |
| Hirabayashi, K | 1 |
| Kinugawa, S | 1 |
| Yokota, T | 1 |
| Matsushima, S | 1 |
| Suga, T | 1 |
| Kadoguchi, T | 1 |
| Fukushima, A | 1 |
| Homma, T | 1 |
| Mizushima, W | 1 |
| Masaki, Y | 1 |
| Furihata, T | 1 |
| Katsuyama, R | 1 |
| Okita, K | 1 |
| Tsutsui, H | 1 |
| Niture, NT | 1 |
| Ansari, AA | 1 |
| Naik, SR | 1 |
| Okazaki, S | 1 |
| Takahashi, T | 1 |
| Iwamura, T | 1 |
| Nakaki, J | 1 |
| Sekiya, Y | 1 |
| Yagi, M | 1 |
| Kumagai, H | 1 |
| Sato, M | 1 |
| Sakami, S | 1 |
| Nitta, A | 1 |
| Kawai, K | 1 |
| Kainoh, M | 1 |
| Yu, Y | 1 |
| Wu, Y | 1 |
| Wen, G | 1 |
| Yang, W | 1 |
| Xing, Y | 1 |
| Ye, S | 1 |
| Heng, XP | 1 |
| Li, L | 1 |
| Huang, SP | 1 |
| Lin, MX | 1 |
| Zhuang, HS | 1 |
| Yan, QF | 1 |
| Yang, LQ | 1 |
| Lin, Q | 1 |
| Cheng, XL | 1 |
| Chen, ML | 1 |
| Chen, YC | 1 |
| Lan, YL | 1 |
| Wang, ZT | 1 |
| Yao, SH | 1 |
| Zhang, ZS | 1 |
| Chan, DC | 1 |
| Lan, KC | 1 |
| Wang, CC | 1 |
| Chen, CM | 1 |
| Chao, SC | 1 |
| Tsai, KS | 1 |
| Yang, RS | 1 |
| Liu, SH | 1 |
| Watanabe, Y | 1 |
| Nakayama, K | 1 |
| Taniuchi, N | 1 |
| Horai, Y | 1 |
| Kuriyama, C | 1 |
| Ueta, K | 1 |
| Arakawa, K | 1 |
| Senbonmatsu, T | 1 |
| Shiotani, M | 1 |
| Byrne, FM | 1 |
| Cheetham, S | 1 |
| Vickers, S | 1 |
| Chapman, V | 1 |
| Shukr, MH | 1 |
| Eltablawy, NA | 1 |
| Liu, HJ | 1 |
| Zhang, CY | 1 |
| Song, F | 1 |
| Xiao, T | 1 |
| Meng, J | 1 |
| Liang, CL | 1 |
| Li, S | 1 |
| Zhang, B | 1 |
| Liu, YR | 1 |
| Sun, T | 1 |
| Zhou, HG | 1 |
| Shahar Yar, M | 1 |
| Pillai, K | 1 |
| Chadha, GS | 1 |
| Morris, ME | 1 |
| Goto, T | 1 |
| Nakayama, R | 1 |
| Yamanaka, M | 2 |
| Takata, M | 1 |
| Takazawa, T | 1 |
| Watanabe, K | 2 |
| Maruta, K | 1 |
| Nagata, R | 1 |
| Nagamine, J | 1 |
| Tsuchida, A | 2 |
| Kato, H | 1 |
| Matsumoto, Y | 1 |
| Ishii, M | 1 |
| Hayashi, Y | 1 |
| Miyazaki, S | 1 |
| Sugita, T | 1 |
| Sumiya, E | 1 |
| Sekimizu, K | 1 |
| Hirukawa, H | 1 |
| Kaneto, H | 2 |
| Shimoda, M | 1 |
| Kimura, T | 1 |
| Okauchi, S | 1 |
| Obata, A | 1 |
| Kohara, K | 1 |
| Hamamoto, S | 1 |
| Tawaramoto, K | 1 |
| Hashiramoto, M | 1 |
| Kaku, K | 1 |
| Zhao, L | 1 |
| Pan, Y | 1 |
| Peng, K | 1 |
| Li, D | 1 |
| Tong, C | 1 |
| Liang, G | 1 |
| Gliem, M | 1 |
| Klotz, L | 1 |
| van Rooijen, N | 1 |
| Hartung, HP | 1 |
| Jander, S | 1 |
| Khan, S | 2 |
| Panda, BP | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| El-Sahar, AE | 1 |
| Safar, MM | 1 |
| Zaki, HF | 1 |
| Attia, AS | 1 |
| Ain-Shoka, AA | 1 |
| Macan, M | 1 |
| Vukšić, A | 1 |
| Žunec, S | 1 |
| Konjevoda, P | 1 |
| Lovrić, J | 1 |
| Kelava, M | 1 |
| Štambuk, N | 1 |
| Vrkić, N | 1 |
| Bradamante, V | 1 |
| Jain, S | 2 |
| Sharma, BM | 1 |
| Sharma, B | 2 |
| Griggs, RB | 1 |
| Donahue, RR | 1 |
| Adkins, BG | 1 |
| Anderson, KL | 1 |
| Thibault, O | 1 |
| Taylor, BK | 1 |
| Kunasegaran, T | 2 |
| Mustafa, MR | 2 |
| Murugan, DD | 2 |
| Achike, FI | 2 |
| Jin, X | 1 |
| Liu, L | 1 |
| Zhou, Z | 1 |
| Ge, J | 1 |
| Yao, T | 1 |
| Shen, C | 1 |
| Abd El-Twab, SM | 1 |
| Mohamed, HM | 1 |
| Mahmoud, AM | 1 |
| Refaat, R | 1 |
| Sakr, A | 1 |
| Salama, M | 1 |
| El Sarha, A | 1 |
| Eom, YS | 1 |
| Gwon, AR | 1 |
| Kwak, KM | 1 |
| Kim, JY | 1 |
| Yu, SH | 1 |
| Lee, S | 1 |
| Kim, YS | 1 |
| Park, IB | 1 |
| Kim, KW | 1 |
| Lee, K | 1 |
| Kim, BJ | 1 |
| Okoduwa, SI | 1 |
| Umar, IA | 1 |
| James, DB | 1 |
| Inuwa, HM | 1 |
| Mamindla, S | 1 |
| Koganti, VSRGP | 1 |
| Ravouru, N | 1 |
| Koganti, B | 1 |
| Gumieniczek, A | 7 |
| Hopkała, H | 2 |
| Zabek, A | 1 |
| Mizukami, H | 2 |
| Wada, R | 2 |
| Yonezawa, A | 1 |
| Sugawara, A | 2 |
| Yagihashi, S | 2 |
| Ghanaat-Pour, H | 1 |
| Sjöholm, A | 1 |
| Gropler, RJ | 1 |
| Biscetti, F | 1 |
| Straface, G | 1 |
| Arena, V | 1 |
| Stigliano, E | 1 |
| Pecorini, G | 1 |
| Rizzo, P | 1 |
| De Angelis, G | 1 |
| Iuliano, L | 1 |
| Ghirlanda, G | 1 |
| Flex, A | 1 |
| Yoshiuchi, K | 1 |
| Matsuoka, TA | 1 |
| Kasami, R | 1 |
| Kohno, K | 1 |
| Iwawaki, T | 1 |
| Nakatani, Y | 1 |
| Yamasaki, Y | 1 |
| Shimomura, I | 1 |
| Matsuhisa, M | 2 |
| Krzywdzińska, M | 1 |
| Nowak, M | 1 |
| Gad, MZ | 1 |
| Ehssan, NA | 1 |
| Ghiet, MH | 1 |
| Wahman, LF | 1 |
| Lu, YX | 1 |
| Sun, YX | 1 |
| Wang, LY | 1 |
| Cheng, WM | 1 |
| Hu, XY | 1 |
| Yang, KJ | 1 |
| Noh, JR | 1 |
| Kim, YH | 1 |
| Gang, GT | 1 |
| Hwang, JH | 1 |
| Yang, SJ | 1 |
| Yeom, YI | 1 |
| Lee, CH | 1 |
| Konturek, PC | 1 |
| Brzozowski, T | 1 |
| Burnat, G | 1 |
| Szlachcic, A | 1 |
| Koziel, J | 1 |
| Kwiecien, S | 1 |
| Konturek, SJ | 1 |
| Harsch, IA | 1 |
| El-Bassossy, HM | 1 |
| Fahmy, A | 1 |
| Badawy, D | 1 |
| Baraka, AM | 1 |
| Deif, MM | 1 |
| Yeom, JA | 1 |
| Kim, ES | 1 |
| Park, HS | 1 |
| Ham, DS | 1 |
| Sun, C | 1 |
| Kim, JW | 1 |
| Cho, JH | 1 |
| Yoon, KH | 1 |
| Song, LL | 1 |
| Xiao, JZ | 1 |
| Yang, WY | 1 |
| Liu, BB | 1 |
| Sengupta, P | 1 |
| Nandi, U | 1 |
| Pal, TK | 1 |
| Kono, T | 1 |
| Ahn, G | 1 |
| Moss, DR | 1 |
| Gann, L | 1 |
| Zarain-Herzberg, A | 1 |
| Nishiki, Y | 1 |
| Fueger, PT | 1 |
| Ogihara, T | 1 |
| Evans-Molina, C | 1 |
| Elrashidy, RA | 1 |
| Asker, ME | 1 |
| Mohamed, HE | 1 |
| Roman-Ramos, R | 1 |
| Fortis-Barrera, A | 1 |
| Angeles-Mejia, S | 1 |
| Banderas-Dorantes, TR | 1 |
| Zamilpa-Alvarez, A | 1 |
| Diaz-Flores, M | 1 |
| Jasso, I | 1 |
| Blancas-Flores, G | 1 |
| Gomez, J | 1 |
| Yu, Q | 1 |
| Liu, D | 1 |
| Ashoff, A | 1 |
| Qadri, F | 1 |
| Eggers, R | 1 |
| Jöhren, O | 1 |
| Raasch, W | 1 |
| Dendorfer, A | 1 |
| Owczarek, B | 1 |
| Pawlikowska, B | 1 |
| Tang, SS | 1 |
| Wang, XY | 1 |
| Liao, MX | 1 |
| Ding, QL | 1 |
| Li, JC | 1 |
| Tsirella, E | 1 |
| Mavrakanas, T | 1 |
| Rager, O | 1 |
| Tsartsalis, S | 1 |
| Kallaras, K | 1 |
| Kokkas, B | 1 |
| Mironidou-Tzouveleki, M | 1 |
| Tawfik, MK | 2 |
| Wang, QJ | 1 |
| Zha, XJ | 1 |
| Kang, ZM | 1 |
| Xu, MJ | 1 |
| Huang, Q | 1 |
| Zou, DJ | 1 |
| Wu, X | 1 |
| Ding, X | 1 |
| Preuss, HG | 1 |
| Echard, B | 1 |
| Fu, J | 1 |
| Perricone, NV | 1 |
| Bagchi, D | 1 |
| Kaylor, M | 1 |
| Zhuang, C | 1 |
| Sim, YB | 1 |
| Park, SH | 1 |
| Kang, YJ | 1 |
| Kim, SS | 1 |
| Kim, CH | 1 |
| Kim, SJ | 1 |
| Jung, JS | 1 |
| Ryu, OH | 1 |
| Choi, MG | 1 |
| Suh, HW | 1 |
| Rahigude, A | 1 |
| Bhutada, P | 1 |
| Kaulaskar, S | 1 |
| Aswar, M | 1 |
| Otari, K | 1 |
| Yuan, YM | 1 |
| Gao, JW | 1 |
| Shi, Z | 1 |
| Huang, P | 1 |
| Lu, YS | 1 |
| Yao, MC | 1 |
| Huang, M | 1 |
| Ueno, T | 1 |
| Teraoka, N | 1 |
| Takasu, S | 1 |
| Nakano, K | 1 |
| Takahashi, M | 2 |
| Yamamoto, M | 1 |
| Fujii, G | 1 |
| Komiya, M | 1 |
| Yanaka, A | 1 |
| Wakabayashi, K | 1 |
| Mutoh, M | 1 |
| Chen, J | 1 |
| Zheng, Q | 1 |
| Xu, X | 1 |
| Masoad, RE | 1 |
| Ewais, MM | 1 |
| Abd El-All, HS | 1 |
| Nayak, AK | 1 |
| Pal, D | 1 |
| Hasnain, SM | 1 |
| Sohda, T | 5 |
| Kawamatsu, Y | 2 |
| Fujita, T | 3 |
| Meguro, K | 5 |
| Ikeda, H | 7 |
| Anjaneyulu, M | 1 |
| Ramarao, P | 2 |
| Nagisa, Y | 1 |
| Kato, K | 1 |
| Murakoshi, H | 1 |
| Odaka, H | 2 |
| Yoshikawa, K | 1 |
| Sugiyama, Y | 4 |
| Ishida, H | 1 |
| Takizawa, M | 1 |
| Ozawa, S | 1 |
| Nakamichi, Y | 1 |
| Yamaguchi, S | 1 |
| Katsuta, H | 1 |
| Tanaka, T | 1 |
| Maruyama, M | 1 |
| Katahira, H | 1 |
| Yoshimoto, K | 1 |
| Itagaki, E | 1 |
| Nagamatsu, S | 1 |
| Sonta, T | 1 |
| Inoguchi, T | 1 |
| Tsubouchi, H | 1 |
| Sekiguchi, N | 1 |
| Kobayashi, K | 2 |
| Matsumoto, S | 1 |
| Utsumi, H | 1 |
| Nawata, H | 1 |
| Dong, FQ | 1 |
| Cai, WM | 1 |
| Li, Q | 1 |
| Ruan, Y | 1 |
| Zheng, FP | 1 |
| Zhang, Z | 1 |
| Kudo, T | 1 |
| Akiyama, M | 1 |
| Kuriyama, K | 1 |
| Sudo, M | 1 |
| Moriya, T | 1 |
| Shibata, S | 1 |
| Kamei, Y | 1 |
| Ezaki, O | 1 |
| Majithiya, JB | 2 |
| Paramar, AN | 1 |
| Srinivasan, K | 1 |
| Viswanad, B | 1 |
| Asrat, L | 1 |
| Kaul, CL | 1 |
| Parmar, AN | 1 |
| Trivedi, CJ | 1 |
| Rodriguez, WE | 1 |
| Tyagi, N | 1 |
| Joshua, IG | 1 |
| Passmore, JC | 1 |
| Fleming, JT | 1 |
| Falcone, JC | 1 |
| Tyagi, SC | 1 |
| Roliński, J | 1 |
| Bojarska-Junak, A | 1 |
| Toba, H | 1 |
| Miki, S | 1 |
| Shimizu, T | 1 |
| Yoshimura, A | 1 |
| Inoue, R | 1 |
| Sawai, N | 1 |
| Tsukamoto, R | 1 |
| Murakami, M | 1 |
| Morita, Y | 1 |
| Nakayama, Y | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Shen, JG | 1 |
| Kong, JX | 1 |
| Ohga, S | 1 |
| Shikata, K | 1 |
| Yozai, K | 1 |
| Okada, S | 1 |
| Ogawa, D | 1 |
| Usui, H | 1 |
| Wada, J | 1 |
| Shikata, Y | 1 |
| Makino, H | 2 |
| Matsumoto, T | 1 |
| Noguchi, E | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Sahilli, M | 1 |
| Irat, AM | 1 |
| Işik, AC | 1 |
| Karasu, C | 1 |
| Ozansoy, G | 1 |
| Ari, N | 1 |
| Itakura, Y | 1 |
| Nakagawa, T | 1 |
| Noguchi, H | 1 |
| Taiji, M | 1 |
| Zhang, HY | 1 |
| Zhang, XM | 1 |
| Shen, F | 1 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Yamagishi, S | 1 |
| Ogasawara, S | 1 |
| Yajima, N | 1 |
| Takada, J | 1 |
| Fonseca-Alaniz, MH | 1 |
| de Campos, TB | 1 |
| Andreotti, S | 1 |
| Campana, AB | 1 |
| Okamoto, M | 1 |
| Borges-Silva, Cd | 1 |
| Machado, UF | 1 |
| Lima, FB | 1 |
| Sturis, J | 1 |
| Pugh, WL | 1 |
| Tang, J | 1 |
| Polonsky, KS | 1 |
| Iritani, N | 1 |
| Fukuda, H | 1 |
| Hofmann, C | 2 |
| Lorenz, K | 2 |
| Williams, D | 1 |
| Palazuk, BJ | 2 |
| Colca, JR | 5 |
| Tominaga, M | 1 |
| Igarashi, M | 1 |
| Daimon, M | 1 |
| Eguchi, H | 1 |
| Matsumoto, M | 1 |
| Sekikawa, A | 1 |
| Yamatani, K | 1 |
| Sasaki, H | 1 |
| Towns, R | 1 |
| Kostyo, JL | 1 |
| Shi, ZQ | 1 |
| Wan, C | 1 |
| Lekas, M | 1 |
| Rodgers, CD | 1 |
| Giacca, A | 1 |
| Kawamori, R | 1 |
| Vranic, M | 1 |
| Murase, K | 1 |
| Suzuki, M | 1 |
| Tayuki, N | 1 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Nagao, K | 1 |
| Shinkai, H | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Kadowaki, T | 1 |
| Takamura, T | 1 |
| Ando, H | 1 |
| Nagai, Y | 1 |
| Yamashita, H | 1 |
| Nohara, E | 1 |
| Tang, Y | 1 |
| Osawa, H | 1 |
| Onuma, H | 1 |
| Nishimiya, T | 1 |
| Ochi, M | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Maeda, S | 1 |
| Sugimoto, T | 1 |
| Kikkawa, R | 1 |
| Suzuki, A | 1 |
| Yasuno, T | 1 |
| Kojo, H | 1 |
| Hirosumi, J | 1 |
| Mutoh, S | 1 |
| Notsu, Y | 1 |
| Mizuno, K | 1 |
| Momose, Y | 3 |
| Hofmann, CA | 1 |
| Edwards, CW | 1 |
| Hillman, RM | 2 |
| Dailey, CF | 1 |
| Dinh, DM | 1 |
| Melchior, GW | 1 |
| Spilman, CH | 1 |
| Hatanaka, C | 1 |
| Oi, S | 1 |
| Taketomi, S | 1 |
| Shimura, Y | 1 |
3 reviews available for pioglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles | 1999 |
[Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Re | 2001 |
183 other studies available for pioglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experime | 1998 |
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Z | 2001 |
Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents.
Topics: Animals; Binding Sites; Chemical and Drug Induced Liver Injury; COS Cells; Diabetes Mellitus, Experi | 2005 |
Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.
Topics: Animals; Chemistry Techniques, Synthetic; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypo | 2012 |
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Reg | 2014 |
Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
Topics: Animals; Blood Glucose; Computer Simulation; Diabetes Mellitus, Experimental; Drug Design; Female; G | 2014 |
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Huma | 2015 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Tra | 2016 |
Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetes | 2022 |
PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions.
Topics: Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Blood Glucose; Body Weight; Calcinosis; Diabete | 2021 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Sub | 2022 |
Preparation and in-vitro, in-vivo characterisation of pioglitazone loaded chitosan/PEG blended PLGA biocompatible nanoparticles.
Topics: Animals; Chitosan; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Carriers; Nanopa | 2022 |
Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes.
Topics: Animals; Caveolin 1; Diabetes Mellitus, Experimental; Disease Models, Animal; Interleukin-6; Mice; N | 2022 |
Efficiency comparison of an isoeugenol-derivated compound, eugenosedin-A, with glibenclamide and pioglitazone in protecting cardiovascular dysfunction of diabetic SHR.
Topics: Animals; Diabetes Mellitus, Experimental; Glyburide; Hypoglycemic Agents; Pioglitazone; Rats; Rats, | 2023 |
Pioglitazone attenuates ischaemic stroke aggravation by blocking PPARγ reduction and inhibiting chronic inflammation in diabetic mice.
Topics: Animals; Brain Ischemia; Diabetes Mellitus, Experimental; Inflammation; Ischemic Stroke; Mice; NLR F | 2022 |
Ameliorative effect of selenium yeast in combination with pioglitazone on diabetes outcomes in streptozotocin-induced.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resist | 2022 |
Anti-diabetic effect of cotreatment with resveratrol and pioglitazone in diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Li | 2023 |
Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming.
Topics: Animals; Diabetes Mellitus, Experimental; Gout; Hereditary Autoinflammatory Diseases; Inflammasomes; | 2023 |
Pioglitazone Alters Ace/Ace 2 Balance to Favour Ace2 Independently Of Glycaemia Levels in Diabetic Rat Heart.
Topics: Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Lipids; Pi | 2023 |
Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Hypoglycemic Agents; Mice; Molecular Docking | 2023 |
Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Infl | 2023 |
Pioglitazone-loaded three-dimensional composite polymeric scaffolds: A proof of concept study in wounded diabetic rats.
Topics: Animals; Bandages; Chitosan; Diabetes Mellitus, Experimental; Drug Liberation; Hypromellose Derivati | 2019 |
Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Kidney; Male; Pioglitazone; Rats, Zucker; | 2019 |
Design, synthesis and biological evaluation of theophylline containing variant acetylene derivatives as α-amylase inhibitors.
Topics: Acarbose; Acetylene; alpha-Amylases; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Exper | 2019 |
Ameliorative effect of combined low dose of Pioglitazone and omega-3 on spermatogenesis and steroidogenesis in diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Rel | 2020 |
Impact of discontinuation of fish oil after pioglitazone-fish oil combination therapy in diabetic KK mice.
Topics: Adiponectin; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Body Weight; Cell Differentiatio | 2020 |
MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2020 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progres | 2019 |
Evaluation of burst release and sustained release of pioglitazone-loaded fibrous mats on diabetic wound healing: an
Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Mice; NIH 3T3 Cells; Pioglita | 2020 |
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet | 2020 |
Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes.
Topics: Adipogenesis; Animals; Bone Marrow Cells; Cellular Reprogramming; Chemokine CXCL12; Diabetes Mellitu | 2020 |
Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diet, High-Fat; Hyperinsuli | 2020 |
Novel therapeutic intervention of coenzyme Q10 and its combination with pioglitazone on the mRNA expression level of adipocytokines in diabetic rats.
Topics: Adipokines; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Gen | 2020 |
Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy.
Topics: Animals; Baroreflex; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2020 |
Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Hemodynamics; Hypertension; Hypoglycemic Agen | 2020 |
Caffeine modulates pharmacokinetic and pharmacodynamic profiles of pioglitazone in diabetic rats: Impact on therapeutics.
Topics: Animals; Caffeine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2021 |
Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Fibrosis; Focal Adhesion Kinase 1; Male; Mice; Mice, Inbre | 2021 |
The effectiveness comparisons of eugenosedin-A, glibenclamide and pioglitazone on diabetes mellitus induced by STZ/NA and high-fat diet in SHR.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Glyburide; Hypertension; Hy | 2021 |
Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.
Topics: Animals; Aspalathus; Atorvastatin; Blood Glucose; Chalcones; Diabetes Mellitus, Experimental; Diabet | 2021 |
Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Cell Movement; Cell Proliferation; Cell Survival; Collagen; D | 2021 |
Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents.
Topics: 3T3 Cells; Animals; Binding Sites; Catalytic Domain; Cell Survival; Diabetes Mellitus, Experimental; | 2021 |
Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Topics: 3T3 Cells; Animals; Blood Glucose; Calcium; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mel | 2017 |
Pioglitazone improves the ability of learning and memory via activating ERK1/2 signaling pathway in the hippocampus of T2DM rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hippoca | 2017 |
Effects of Lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice.
Topics: Animals; Bacteroides; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2017 |
Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
Topics: Action Potentials; Alloxan; Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Expe | 2017 |
Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus.
Topics: Animals; Apolipoproteins E; Caspase 1; Diabetes Mellitus, Experimental; Down-Regulation; Enzyme-Link | 2017 |
Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cholesterol; Combined Modality Therapy; Diabetes Mellitus, Experimental; Dia | 2018 |
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe | 2017 |
Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diab | 2017 |
Effects of pioglitazone on ventricular myocyte shortening and Ca(2+) transport in the Goto-Kakizaki type 2 diabetic rat.
Topics: Animals; Biological Transport; Calcium Signaling; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2018 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug | 2018 |
Mitochondrial dysfunction contribute to diabetic neurotoxicity induced by streptozocin in mice: protective effect of Urtica dioica and pioglitazone.
Topics: Animals; Antioxidants; Biomarkers; Brain; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dr | 2018 |
Effect of pioglitazone on vasopressor responses to adrenergic agonists and angiotensin II in diabetic and non-diabetic spontaneously hypertensive rats.
Topics: Adrenergic Agonists; Angiotensin II; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hemody | 2018 |
Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Sy | 2018 |
Ethanolic seeds extract of Centratherum anthelminticum reduces oxidative stress in type 2 diabetes.
Topics: Alanine Transaminase; Animals; Antioxidants; Asteraceae; Bilirubin; Creatine Kinase; Diabetes Mellit | 2018 |
Whole-Organism Chemical Screening Identifies Modulators of Pancreatic β-Cell Function.
Topics: Animals; Animals, Genetically Modified; Diabetes Mellitus, Experimental; Gene Expression Profiling; | 2018 |
Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2018 |
Physicochemical and pharmacodynamic evaluation of pioglitazone binary systems with hydrophilic carriers.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Carriers; Drug Liberation; Hydrophobic and Hydrophili | 2019 |
Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycogen Synthas | 2013 |
Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals | 2013 |
Streptozotocin diabetes and insulin resistance impairment of spermatogenesis in adult rat testis: central vs. local mechanism.
Topics: Animals; Diabetes Mellitus, Experimental; Infertility, Male; Insulin; Insulin Resistance; Male; Panc | 2012 |
Circadian-clock system in mouse liver affected by insulin resistance.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Circadian Rhythm; Diabetes Mellitus, Experime | 2013 |
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Gene Expressio | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pr | 2013 |
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, | 2013 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; D | 2014 |
Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Exenatide; Free Radical Scavengers; Hypogly | 2014 |
The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats.
Topics: Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Therapy, | 2014 |
Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Fluorescent Antibody | 2014 |
Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab | 2014 |
Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.
Topics: Amiloride; Animals; Blood Glucose; Body Weight; Citrate (si)-Synthase; Diabetes Mellitus, Experiment | 2014 |
Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mell | 2014 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Ca | 2014 |
[Effect of pioglitazone on the expression of TLR4 in renal tissue of diabetic rats].
Topics: Albuminuria; Animals; Blotting, Western; C-Reactive Protein; Diabetes Mellitus, Experimental; Disacc | 2014 |
Hydrochloride pioglitazone protects diabetic rats against podocyte injury through preserving glomerular podocalyxin expression.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Hypoglycemic Agents; I | 2014 |
[Effect of dangua recipe on glycolipid metabolism and VCAM-1 and its mRNA expression level in Apo E(-/-) mice with diabetes mellitus].
Topics: Animals; Apolipoproteins E; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D | 2014 |
PPARγ is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages.
Topics: Adult; Aged; Animals; Cartilage; Chondrocytes; Collagen; Diabetes Mellitus, Experimental; Dinoprosto | 2015 |
Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
Topics: Adipose Tissue; Animals; Body Weight; Canagliflozin; Cells, Cultured; Diabetes Mellitus, Experimenta | 2015 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neu | 2015 |
Development and optimization of novel controlled-release pioglitazone provesicular powders using 3² factorial design.
Topics: Animals; Blood Glucose; Chemistry, Pharmaceutical; Cholesterol; Delayed-Action Preparations; Diabete | 2015 |
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
Topics: 3-Mercaptopropionic Acid; Animals; Blood Glucose; Cell Line; Cell Survival; Diabetes Mellitus, Exper | 2015 |
Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Topics: 3T3-L1 Cells; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; F | 2015 |
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.
Topics: Administration, Intravenous; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Exp | 2015 |
Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; 3T3-L1 Cells; Adipogenesis; Animals; Diabetes Mellitus, Exper | 2015 |
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.
Topics: Animals; Bombyx; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Drug Evaluation, | 2015 |
Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Insulin Receptor Substrate Protein | 2015 |
Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Cell Line; Curcumin; Dexamethas | 2015 |
Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke.
Topics: Animals; Anticoagulants; Cell Polarity; Cerebral Hemorrhage; Diabetes Mellitus, Experimental; Diseas | 2015 |
Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Prog | 2015 |
Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Brain Ischemia; Carotid Artery, Com | 2015 |
Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Brain Ischemia; Carotid Artery, Com | 2015 |
Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus.
Topics: Animals; Attention; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Calcium Channels; Capillar | 2016 |
Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.
Topics: Administration, Oral; Analgesics; Animals; Central Nervous System Sensitization; Cold Temperature; D | 2016 |
The bioflavonoid quercetin synergises with PPAR-γ agonist pioglitazone in reducing angiotensin-II contractile effect in fructose-streptozotocin induced diabetic rats.
Topics: Angiotensin II; Animals; Aorta; Diabetes Mellitus, Experimental; Fructose; Male; Muscle Contraction; | 2016 |
Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation.
Topics: Animals; Anti-Inflammatory Agents; Bone Marrow; Diabetes Mellitus, Experimental; Diet, High-Fat; Gly | 2016 |
Taurine and pioglitazone attenuate diabetes-induced testicular damage by abrogation of oxidative stress and up-regulation of the pituitary-gonadal axis.
Topics: Animals; Diabetes Mellitus, Experimental; Inflammation Mediators; Male; Oxidative Stress; Pioglitazo | 2016 |
Effect of ruthenium red, a ryanodine receptor antagonist in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Brain; Calcium Channel Blockers; Dementia; Diabetes Mell | 2016 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2016 |
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
Topics: Adamantane; Animals; Biomarkers; Bone Density; Bone Resorption; Diabetes Mellitus, Experimental; Dia | 2016 |
Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Effect of Cinnamomum cassia on the Pharmacokinetics and Pharmacodynamics of Pioglitazone.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Biomarkers; Blood Glucose; | 2017 |
Quercetin and pioglitazone synergistically reverse endothelial dysfunction in isolated aorta from fructose-streptozotocin (F-STZ)-induced diabetic rats.
Topics: Animals; Aorta; Diabetes Mellitus, Experimental; Drug Synergism; Endothelium, Vascular; Fructose; Ma | 2017 |
Protective effects of a PPARgamma agonist pioglitazone on anti-oxidative system in testis of diabetic rabbits.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Experimental; Glutathione; H | 2008 |
Suppression of post-prandial hyperglycaemia by pioglitazone improved islet fibrosis and macrophage migration in the Goto-Kakizaki rat.
Topics: Animals; Cell Death; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Insulin-Se | 2008 |
Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Topics: Animals; Diabetes Mellitus, Experimental; Exenatide; Gene Expression Regulation; Glucokinase; Hypogl | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.
Topics: Anilides; Animals; Benzophenones; Blood Flow Velocity; Blood Glucose; Collateral Circulation; Diabet | 2009 |
Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice.
Topics: Adiponectin; Adipose Tissue; Animals; Cell Size; Diabetes Mellitus, Experimental; DNA-Binding Protei | 2009 |
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Catalase; Diabetes Mellitus, Experimental; | 2009 |
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Dietary Fats; Gluc | 2010 |
Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Antioxidants; Body Weight; C-Reactive Protein; Diabetes Mellitus, Experimental; Dietary Fat | 2010 |
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
Topics: Acyl-CoA Dehydrogenase; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; CD36 Antigens; C | 2010 |
Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Male; Pioglitazone; Protective Agents; Rats; Rats, Wistar; | 2010 |
Cinnamaldehyde protects from the hypertension associated with diabetes.
Topics: Acetylcholinesterase; Acrolein; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cal | 2011 |
Role of activation of 5'-adenosine monophosphate-activated protein kinase in gastric ulcer healing in diabetic rats.
Topics: Acetic Acid; Animals; Blood Glucose; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experi | 2011 |
Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; | 2011 |
[The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Pe | 2011 |
Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Area Under Curve; Blood G | 2012 |
PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.
Topics: Animals; Base Sequence; Binding Sites; Blood Glucose; Calcium; Cell Cycle; Cyclin-Dependent Kinase 5 | 2012 |
Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 2012 |
Antioxidant and anti-inflammatory effects of a hypoglycemic fraction from Cucurbita ficifolia Bouché in streptozotocin-induced diabetes mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Cucurbita; Cytokines; Diabetes Melli | 2012 |
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.
Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabet | 2012 |
Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression.
Topics: Animals; Apoptosis; Blood Glucose; Capillaries; Diabetes Mellitus, Experimental; Hypoglycemic Agents | 2012 |
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.
Topics: Animals; Antioxidants; Aqueous Humor; Carbamates; Diabetes Mellitus, Experimental; Glutathione Perox | 2012 |
PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; | 2012 |
Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.
Topics: Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Resorption; Calcium; Collagen Type I; | 2012 |
Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Catalase | 2012 |
Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Hydrogen; Hypoglycemic Agents; Insulin Resistance; Oxidati | 2012 |
Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs.
Topics: Adiponectin; Animals; Blood Pressure; Cells, Cultured; Coronary Vessels; Diabetes Mellitus, Experime | 2012 |
Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Grifola; Hypog | 2012 |
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.
Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2012 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabe | 2012 |
Herb-drug pharmacokinetic interaction between radix astragali and pioglitazone in rats.
Topics: Animals; Astragalus Plant; Astragalus propinquus; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2012 |
Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
Topics: Aberrant Crypt Foci; Adipokines; Animals; Azoxymethane; Biomarkers; Carcinogens; Colorectal Neoplasm | 2012 |
Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herba | 2013 |
Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents | 2012 |
Development, optimization and in vitro-in vivo evaluation of pioglitazone- loaded jackfruit seed starch-alginate beads.
Topics: Alginates; Animals; Artocarpus; Blood Glucose; Calcium Chloride; Chemistry, Pharmaceutical; Delayed- | 2013 |
Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Pioglitazone; | 2003 |
Changes in glycated haemoglobin levels in diabetic rats measured with an automatic affinity HPLC.
Topics: Animals; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Femal | 2003 |
Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits.
Topics: Animals; Ascorbic Acid; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Hypoglycemic Ag | 2003 |
Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.
Topics: Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucose; Heme Oxygenase (Decycli | 2004 |
Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Electron Spin Resonance Spectrosco | 2004 |
Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Immunohistochemistry; Kidney Glomerul | 2004 |
Night-time restricted feeding normalises clock genes and Pai-1 gene expression in the db/db mouse liver.
Topics: Animals; Blood Glucose; Circadian Rhythm; CLOCK Proteins; Diabetes Mellitus, Experimental; Diet, Red | 2004 |
Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Biomarkers; Cell Size; Diabetes Mellitus, Experim | 2005 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experim | 2005 |
Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals.
Topics: Alloxan; Animals; Antioxidants; Diabetes Mellitus, Experimental; Glutathione; Glutathione Peroxidase | 2005 |
Modification of oxidative stress by pioglitazone in the heart of alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Ascorbic Acid; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Dose-Resp | 2005 |
Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dietary Fats; Glipizide; Gluco | 2005 |
Effect of pioglitazone on L-NAME induced hypertension in diabetic rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Body Weight; Catalase; Diabetes Mellitus, E | 2005 |
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.
Topics: Animals; Arterioles; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab | 2006 |
Interleukin-6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment.
Topics: Animals; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin | 2006 |
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Bezafibrate; Blood Glucose; Blotti | 2006 |
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hypoglycemic Agents; Mitogen-Activat | 2006 |
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E | 2007 |
Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats.
Topics: Animals; Aorta; Diabetes Mellitus, Experimental; Endothelin-1; Endothelium, Vascular; Hypoglycemic A | 2007 |
A lack of synergistic interaction between insulin and pioglitazone on reactivity of rat aorta from chronically high dose insulin-treated diabetic rats.
Topics: Animals; Aorta; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes | 2007 |
Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Topics: Animals; Blood Glucose; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Experimental; Diabetes | 2007 |
[The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Female; Gene Expression; Hypoglycemi | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
Topics: Analysis of Variance; Animals; Carbohydrate Metabolism; Cell Movement; Diabetes Mellitus, Experiment | 2008 |
Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes.
Topics: Adipose Tissue; Animals; C-Peptide; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Glu | 2008 |
Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat.
Topics: Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fasting; Glycated Hemoglobin; Hyp | 1995 |
Polyunsaturated fatty acid-mediated suppression of insulin-dependent gene expression of lipogenic enzymes in rat liver.
Topics: Acetyl-CoA Carboxylase; Animals; ATP Citrate (pro-S)-Lyase; Corn Oil; Diabetes Mellitus, Experimenta | 1995 |
Insulin sensitization in diabetic rat liver by an antihyperglycemic agent.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Gene Expression; Glucoki | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Gluco | 1993 |
Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Feeding Behavior; Female; Growth Hormone; H | 1994 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1997 |
Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Imm | 1998 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Me | 1999 |
Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dose-Resp | 1999 |
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Cyclic Nucleotide Phosp | 1999 |
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Diglycerides; Extracellular Matrix | 2000 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; | 2000 |
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resista | 1992 |
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
Topics: Animals; Crosses, Genetic; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Hypoglycemic | 1992 |
Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypoglycemic Agents; In | 1991 |
Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.
Topics: Administration, Oral; Animals; Biological Transport; Diabetes Mellitus, Experimental; Diabetes Melli | 1991 |
Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Mice, Obe | 1991 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyp | 1990 |
Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones.
Topics: Animals; Chemical Phenomena; Chemistry; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; | 1990 |